Evidence map›Paper›PMID 34987382›Full record

ArticleFrontiers in pharmacology2021

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation.

Gang Shen, Lei Shi, Xin Tian, Depei Huang, Hao Chen, Chan Gao, Xudong Shen, Hushan Zhang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Gang ShenDepartment of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Lei ShiDepartment of Thoracic Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Xin TianDepartment of Head and Neck Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Depei HuangThe Medical Department, 3D Medicines Inc., Shanghai, China.
Hao ChenThe Bioinformatics Department, 3D Medicines Inc., Shanghai, China.
Chan GaoThe Medical Department, 3D Medicines Inc., Shanghai, China.
Xudong ShenThe Medical Department, 3D Medicines Inc., Shanghai, China.
Hushan ZhangThe Medical Department, 3D Medicines Inc., Shanghai, China.
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib shows strong clinical activity in first- and second-line treatment of nonsmall-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, especially EGFR T790M. However, when patients develop resistance, there is currently no definite postosimertinib treatment option. Herein, we report a patient with metastatic NSCLC who benefited from almonertinib after developing resistance to osimertinib.

Indexed as

almonertinibEGFRL718QNSCLC-lung adenocarcinoma-EGFR-ALK-BRAF-KRAS-RET-MET-PD-L1-ROS1.TKI-tyrosine kinase inhibitor

Identifiers

PMID34987382
PMCPMC8721274
OpenAlexW4200524158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.